Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

September 2024

Clinical pathology selected abstracts

September 2024—Syphilis, an infectious disease caused by the spirochete bacterium Treponema pallidum, can be transmitted by blood transfusion. Therefore, donor blood has been routinely screened for syphilis since the 1950s. Although a case of transfusion-transmitted syphilis has not been documented in more than 50 years, routine serological testing is still performed because there is not sufficient evidence that it is no longer necessary. Syphilis testing can contribute to disease monitoring for overall public health by identifying infected blood donors so they can seek treatment to prevent further spread. The Transfusion Transmissible Infections Monitoring System (TTIMS) monitors infectious disease and demographic changes in donors who contribute approximately 60 percent of the U.S. blood supply, including at four major blood-collection organizations.

Anatomic pathology selected abstracts

September 2024—Research has shown assessment of tumor-associated stroma to be of reliable prognostic value. The authors conducted a study in which they evaluated the prognostic value of tumor-stroma ratio in a large multicenter cohort of nasopharyngeal carcinoma. They used the conventional H&E-stained slides of 115 cases of nasopharyngeal carcinoma to assess tumor-stroma ratio as described in recent guidelines. The amount of tumor-associated stroma was assessed as a percentage and then tumors were classified as stroma high (more than 50 percent) or stroma low (50 percent or less). Kaplan-Meier curves, a χ2 test, and Cox regression univariable and multivariable analyses were conducted.

Molecular pathology selected abstracts

September 2024—Oncology patients may benefit greatly from whole genome sequencing. Previous studies have suggested that it can provide relevant information pertaining to pediatric cancers, especially in selected cohorts of patients with high-risk disease. However, its clinical utility has not been thoroughly explored in routine clinical practice. The authors of this study examined the benefits of whole genome sequencing (WGS) in a consecutive cohort of pediatric patients from two institutions who required molecular workup for hematological neoplasms and solid tumors. Great Ormond Street Hospital, London, and Cambridge (England) University Hospitals offered WGS to patients with leukemia or solid tumors, respectively.

Q&A column

September 2024
Q. When performing body fluid cell counts, we report total nucleated cells and RBCs. What cell categories should we report on the corresponding differential? Can we group together monocytes, macrophages, and mesothelial cells since it is difficult to distinguish reactive mesothelial cells from monocytes and macrophages? If so, what category name should be applied? Should we report mesothelial cells as a comment or include them in the differential? Read answer.
Q. Are nonlaboratory personnel who perform point-of-care testing required to be tested for visual color discrimination? Or is it sufficient that personnel pass a functional assessment during their competency evaluation to evaluate their ability to provide an accurate result on tests that require interpreting colors? Read answer.

Newsbytes

September 2024—The ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine has created the Sherrie Perkins Research and Innovation Collaboration grant to fund lab medicine research that has the potential to significantly improve patient care.

Put It on the Board

September 2024—The Association for Molecular Pathology and pathologist Michael Laposata, MD, PhD, announced on Aug. 19 the filing of a lawsuit challenging the Food and Drug Administration rule that regulates laboratory-developed test procedures as medical devices under the Federal Food, Drug, and Cosmetic Act. The lawsuit was filed in the U.S. District Court for the Southern District of Texas against the FDA; Robert M. Califf, MD, in his official capacity as commissioner of food and drugs; the U.S. Department of Health and Human Services; and Xavier Becerra, in his official capacity as secretary of HHS.

MARKETPLACE

TRENDING